Cantargia appoints CMO

Cantargia AB, a developer of antibody-based treatments, has appointed Morten Lind Jensen as chief medical officer. Dr Jensen’s experience in autoimmune and inflammatory diseases aligns with Cantargia’s CAN10 antibody programme. He has led clinical development programmes in psoriasis, atopic dermatitis and hidradenitis suppurativa. The CAN10 programme addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Dr Jensen has an MD and PhD from Copenhagen University, Denmark and a diploma in pharmaceutical medicine from the Royal College of Physicians, UK.

Cantargia announced the appointment on 1 April 2025.